Cytokine alterations in CSF and serum samples of patients with a first episode of schizophrenia: results and methodological considerations

[1]  V. Buneva,et al.  Immune System Abnormalities in Schizophrenia: An Integrative View and Translational Perspectives , 2022, Frontiers in Psychiatry.

[2]  S. Wood,et al.  Inflammation in first‐episode psychosis: The contribution of inflammatory biomarkers to the emergence of negative symptoms, a systematic review and meta‐analysis , 2022, Acta psychiatrica Scandinavica.

[3]  K. Domschke,et al.  An observational study investigating cytokine levels in the cerebrospinal fluid of patients with schizophrenia spectrum disorders , 2021, Schizophrenia Research.

[4]  L. Eyler,et al.  Chemokine MCP1 is associated with cognitive flexibility in schizophrenia: A preliminary analysis. , 2021, Journal of psychiatric research.

[5]  M. Ota,et al.  Cerebrospinal Fluid Inflammatory Cytokine Levels in Patients With Major Psychiatric Disorders: A Multiplex Immunoassay Study , 2021, Frontiers in Pharmacology.

[6]  K. Domschke,et al.  Increased IL-8 concentrations in the cerebrospinal fluid of patients with unipolar depression. , 2020, Comprehensive psychiatry.

[7]  Shiva Kumar,et al.  Multi-omics Data Integration, Interpretation, and Its Application , 2020, Bioinformatics and biology insights.

[8]  P. Mehta,et al.  Detection of potential biomarkers associated with outrageous diseases and environmental pollutants by nanoparticle-based immuno-PCR assays. , 2019, Analytical biochemistry.

[9]  A. Malhotra,et al.  Cytokines in cerebrospinal fluid of patients with schizophrenia spectrum disorders: New data and an updated meta-analysis , 2018, Schizophrenia Research.

[10]  B. Miller,et al.  Meta-analysis of Cerebrospinal Fluid Cytokine and Tryptophan Catabolite Alterations in Psychiatric Patients: Comparisons Between Schizophrenia, Bipolar Disorder, and Depression , 2018, Schizophrenia bulletin.

[11]  Shihab Kochumon,et al.  Increased adipose tissue expression of IL‐18R and its ligand IL‐18 associates with inflammation and insulin resistance in obesity , 2017, Immunity, inflammation and disease.

[12]  P. Guest,et al.  Making Sense of Blood-Based Proteomics and Metabolomics in Psychiatric Research , 2015, The international journal of neuropsychopharmacology.

[13]  H. Tumani,et al.  Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. , 2014, Cytokine.

[14]  J. M. Ramsey,et al.  Identification of subgroups of schizophrenia patients with changes in either immune or growth factor and hormonal pathways. , 2014, Schizophrenia bulletin.

[15]  Alan S. Brown,et al.  The Cytokine Model of Schizophrenia: Emerging Therapeutic Strategies , 2014, Biological Psychiatry.

[16]  B. Bogerts,et al.  Immune system and glucose metabolism interaction in schizophrenia: A chicken–egg dilemma , 2014, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[17]  R. Kahn,et al.  Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. , 2014, Schizophrenia bulletin.

[18]  P. Buckley,et al.  A systematic, quantitative review of blood autoantibodies in schizophrenia , 2013, Schizophrenia Research.

[19]  Linan Song,et al.  Multiplexed single molecule immunoassays. , 2013, Lab on a chip.

[20]  P. Guest,et al.  Schizophrenia: Metabolic aspects of aetiology, diagnosis and future treatment strategies , 2013, Psychoneuroendocrinology.

[21]  H. Drexhage,et al.  Evidence for a Dysregulated Immune System in the Etiology of Psychiatric Disorders , 2013, Journal of Neuroimmune Pharmacology.

[22]  Emanuel Schwarz,et al.  Comparison of Peripheral and Central Schizophrenia Biomarker Profiles , 2012, PloS one.

[23]  Petr Dráber,et al.  Rapid and sensitive detection of cytokines using functionalized gold nanoparticle-based immuno-PCR, comparison with immuno-PCR and ELISA. , 2011, Journal of immunological methods.

[24]  A. Patruno,et al.  Dysregulation of chemo-cytokine production in schizophrenic patients versus healthy controls , 2011, BMC Neuroscience.

[25]  H. Figulla,et al.  Circulating Levels of Interleukin-1 Family Cytokines in Overweight Adolescents , 2010, Mediators of inflammation.

[26]  Qin Fu,et al.  Comparison of multiplex immunoassay platforms. , 2010, Clinical chemistry.

[27]  Seungah Lee,et al.  An ultra-sensitive nanoarray chip based on single-molecule sandwich immunoassay and TIRFM for protein detection in biologic fluids. , 2009, The Analyst.

[28]  D. Cohen,et al.  Patients with schizophrenia show raised serum levels of the pro-inflammatory chemokine CCL2: Association with the metabolic syndrome in patients? , 2008, Schizophrenia Research.

[29]  B. Saltin,et al.  Adipose Tissue Interleukin‐18 mRNA and Plasma Interleukin‐18: Effect of Obesity and Exercise , 2007, Obesity.

[30]  C. Ballantyne,et al.  Multiplexed analysis of biomarkers related to obesity and the metabolic syndrome in human plasma, using the Luminex-100 system. , 2005, Clinical chemistry.

[31]  A. Burgess,et al.  Chlorpromazine equivalents: a consensus of opinion for both clinical and research applications , 1997 .

[32]  S. Kay,et al.  The positive and negative syndrome scale (PANSS) for schizophrenia. , 1987, Schizophrenia bulletin.